Home > Search Results: Mikala, Gabor
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
10 p, 496.7 KB Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma : IKEMA subgroup analysis / Facon, Thierry (Lille University Hospital) ; Moreau, Philippe (University of Nantes) ; Martin, Thomas G. (University of California San Francisco) ; Spicka, Ivan (Charles University and General Hospital, Prague, Czech Republic) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital, South Korea) ; Lim, Andrew (Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia) ; Mikala, Gabor (South Pest Central Hospital, Budapest, Hungary) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Yağci, Münci (Gazi University, Ankara, Turkey) ; Cavo, Michele (Bologna University School of Medicine, Italy) ; Yong, Kwee (University College Hospital, London, UK) ; Risse, Marie Laure (Sanofi R&D, Vitry-Sur-Seine, France) ; Asset, Gaëlle (Sanofi R&D, Chilly-Mazarin, France) ; Schwab, Sandrine (Sanofi R&D, Chilly-Mazarin, France) ; Martinez, Gracia (Hospital das Clínicas de São Paulo, Brazil)
In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM). [...]
2022 - 10.1002/hon.3038
Hematological Oncology, Vol. 40 Núm. 5 (december 2022) , p. 1020-1029  
Detailed record - Creative Commons
2.
9 p, 982.6 KB Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics : IKEMA subgroup analysis / Spicka, Ivan (Charles University and General Hospital) ; Moreau, Philippe (University of Nantes) ; Martin, Thomas G. (University of California San Francisco) ; Facon, Thierry (Lille University Hospital) ; Martínez, Gracia (Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital) ; Lim, Andrew (Austin and Repatriation Medical Center) ; Mikala, Gabor (South Pest Central Hospital) ; Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Yağci, Münci (Gazi University) ; Cavo, Michele (Università di Bologna) ; Risse, Marie-Laure (Sanofi (França)) ; Asset, Gaëlle (Sanofi (França)) ; Macé, Sandrine (Sanofi (França)) ; Van de Velde, Helgi (Sanofi) ; Yong, Kwee (University College Hospital) ; Universitat Autònoma de Barcelona
Introduction: The presence of high-risk chromosomal abnormalities [t(4;14), del(17p), and t(14;16)] has been linked with inferior outcomes in patients with multiple myeloma (MM). A prespecified interim analysis of the Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) + carfilzomib (K) and dexamethasone (d; Isa-Kd) significantly improved progression-free survival (PFS) versus Kd in patients with relapsed MM. [...]
2022 - 10.1111/ejh.13835
European Journal of Haematology, Vol. 109 Núm. 5 (november 2022) , p. 504-512  
Detailed record - Creative Commons

See also: similar author names
1 Mikala, G.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with